A new research paper was published in Volume 17, Issue 9 of Aging-US on August 27, 2025, titled, "Deregulated miR-145 and miR-27b in Hutchinson-Gilford progeria syndrome: implications for adipogenesis ...

Children who develop deep wrinkles, stunted growth, and rapidly aging bones and blood vessels as early as 1 to 2 years of age may be suffering from Hutchinson-Gilford Progeria Syndrome (HGPS), a rare ...

One of about 150 people known to have a rare condition that causes rapid aging, he sought to raise awareness and participated in the search for a cure. By Trip Gabriel Sammy Basso, an advocate for ...

The results of a University of Maryland (UMD)-led study could point to new and improved treatment approaches for Hutchinson-Gilford progeria syndrome (HGPS), a rare genetic disorder that causes ...

A team of researchers from the Centro Nacional de Investigaciones Cardiovasculares Carlos III (CNIC), the Centro de Investigaciones Biológicas Margarita Salas (CIB-CSIC), and the Instituto de Ciencias ...

Sentynl, a Zydus Group company, receives worldwide proprietary rights to Zokinvy, adding to portfolio of biopharmaceuticals for rare and ultra-rare diseases Zokinvy is approved in the U.S. (2020), ...

A new breakthrough in a rare genetic disease which causes children to age rapidly has been discovered using 'longevity genes' found in people who live exceptionally long lives—over 100 years old. The ...

Proposed working model. Progerin accumulation induces stress, leading to attenuation of Ang2 expression and secretion and its downstream effector. Ang2-induced activation of Tie2 receptor activates ...

Progeria is an extremely rare genetic disease of childhood characterised by dramatic, premature ageing. The condition, which derives its name from “geras”, the Greek word for old age, is estimated to ...

Hutchinson-Gilford progeria syndrome (HGPS), an extremely rare genetic disorder, arises when a silent point mutation in the gene encoding the nuclear envelope protein lamin A, LMNA, leads to abnormal ...

September 27, 2012 — A farnesyltransferase inhibitor originally intended to treat cancer has improved the conditions of all 25 children in a clinical trial for the rapid-aging disorder ...

In the spring of 2005, families affected by progeria welcomed the news from two studies that uncovered new information about this rare, devastating condition that causes premature aging in children.